Information

Search millions of cases and get court filings, fast docket alerts, and case analytics.

Request a Demo or create your account.

Lawyer? Your firm may have a group account, ask us and we'll let you know.

Click below for detailed party information:

Patent Owner

Sydnexis, Inc.

Petitioner

Eyenovia, Inc.

alt+h	Toggle this page.
alt+u	Toggle Upcoming Events view.
alt+e	Export the docket to Excel.
Filtering / Searching the Docket
ctrl+f	Filter the docket.
ctrl+shift+f	Search docket and documents.
alt+s	Toggle between "Show Only" filtering modes.
alt+d, ctrl+f	System ctrl+f
escape	Clear while in docket filter.
Interactive Timeline
alt+t	Show / re-center case timeline.
alt+↑	Zoom in
alt+↓	Zoom out
alt+←	Pan left
alt+→	Pan right

Eyenovia, Inc. v. Sydnexis, Inc.

IPR2022-00414 | Patent Trial and Appeal Board

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.

Filed Jan. 7, 2022

Terminated July 13, 2023

Judges Jamie Wisz, John New, Susan Mitchell, and Erica Franklin

Case Type Inter Partes Review

Status Final Written Decision - Appealed

Challenged Patent 16/785,418

Patent No. 10,940,145 assignments

Tech Center 1600

Art Unit 1627

Inventors Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun Takruri

Last Updated: 2 weeks, 2 days ago

Filing Date	#	Filing and Exhibits
Entries matching. Show All.
9/14/2023	09-14-2023-Patent_Owner	Event: Notice of Appeal Patent Owner Notice: notice of appeal 39: Patent Owner's Notice of Appeal
7/13/2023	07-13-2023-Board	Event: Final Written Decision (All Claims Cancelled) Board Final Written Decision: original 38: Final Written Decision: original
7/12/2023	07-12-2023-Board	Board Other: Hearing transcript 37: Other: Hearing transcript
5/8/2023	05-08-2023-Board	Board Order: Other 36: Order: Panel Change Order
4/12/2023	04-12-2023-Petitioner	Petitioner Notice: Exhibit list 34: Petitioner's Updated Exhibit List Petitioner Exhibit 1096: Petitioner's Demonstratives for Oral Argument
4/12/2023	04-12-2023-Patent_Owner	Patent Owner Other: other 35: Patent Owner's Demonstratives
4/7/2023	04-07-2023-Patent_Owner	Patent Owner Reply to Opposition 33: Patent Owner's Reply ISO Motion to Exclude Evidence
4/5/2023	04-05-2023-Petitioner	Petitioner Notice: Exhibit list 32: Petitioner's Updated Exhibit List
3/31/2023	03-31-2023-Petitioner	Petitioner Opposition 31: Petitioner’s Opposition to Patent Owner’s Motion to Exclude Evidence Petitioner Exhibit 1089: Excerpts of Sambrook & Russell, Molecular Cloning: A Laboratory Manual, (3d ed., 2001) Petitioner Exhibit 1090: Excerpts of “4.1.3 BUFFER SOLUTIONS” from European Pharmacopoeia, (5th ed., 2004) Petitioner Exhibit 1091: “Calbiochem® Buffers: A guide for the preparation and use of buffers in biological systems,” University of North Caroli-na School of Medicine Department of Pharmacology Petitioner Exhibit 1092: MilliporeSigma web page titled “Buffer Reference Center” Petitioner Exhibit 1093: NIH National Library of Medicine PubChem web page titled “Monosodium phosphate” Petitioner Exhibit 1094: NIH National Library of Medicine PubChem web page titled “Disodium hydrogen phosphate” Petitioner Exhibit 1095: Declaration of Rebecca L. Baker
3/24/2023	03-24-2023-Patent_Owner	Patent Owner Motion: Other 30: Patent Owner's Motion to Exclude Evidence
3/8/2023	03-08-2023-Board	Board Order: on Motion 29: ORDER Setting Oral Argument 37 C.F.R. sec 42.70
3/3/2023	03-03-2023-Patent_Owner	Patent Owner Notice: Other 27: Patent Owner's Request for Oral Argument Patent Owner Notice: Updated Mandatory Notice 28: Patent Owner's Updated Mandatory Notices
3/3/2023	03-03-2023-Petitioner	Petitioner Other: other 26: Petitioner's Request for Oral Argument
2/24/2023	02-24-2023-Patent_Owner	Patent Owner Notice: Other 25: Patent Owner's Sur-Reply
2/6/2023	02-06-2023-Petitioner	Petitioner Notice: Other 24: Petitioner's Notice of Supplemental Evidence
1/23/2023	01-23-2023-Patent_Owner	Patent Owner Other: other 23: Patent Owner's Objections to Evidence
1/13/2023	01-13-2023-Petitioner	Petitioner Pet Reply to PO Resp 22: Petitioner's Reply to Patent Owner's Response Petitioner Exhibit 1071: Freedom of Information Act (FOIA) Request No. 58532 filed with National Library of Medicine on August 7, 2022 and automated response. Petitioner Exhibit 1072: National Library of Medicine Freedom of Information Act (FOIA) Request No. 58532 and August 8, 2022 response. Petitioner Exhibit 1078: December 9, 2022, Deposition Transcript of Paul A. Laskar, Ph.D. Petitioner Exhibit 1079: Appendix 1: 1 Preparation of Reagents and Buffers Used in Molecular Cloning, in Sambrook, J. F., & Russell, D. W., Molecular cloning: A laboratory manual (3d ed. 2001). Petitioner Exhibit 1080: United States Patent Publication No. 2011/0184017 Al to Kanzawa et al. Petitioner Exhibit 1081: Chapter 4: Reagents, in Directorate for the Quality of Medicine & Health Care of the Council of Europe (EDQM), European Pharmacopoeia (5th ed. 2004) Petitioner Exhibit 1082: Buffers: A guide for the preparation and use of buffers in biological systems, Calbiochem (2006), available at https://www.med.unc.edu/pharm/sondeklab/wp-content/uploads/sites/868/2018/10/buffers_calbiochem.pdf (last visited Dec. 5, 2022). Petitioner Exhibit 1083: Buffer Reference Center, MilliporeSigma, available at https://www.sigmaaldrich.com/US/en/technical-documents/protocol/protein-biology/protein-concentration-and-buffer-exchange/buffer-reference-center (last visited Dec. 5, 2022). Petitioner Exhibit 1084: Monosodium phosphate, PubChem, available at https://pubchem.ncbi.nlm.nih.gov/compound/Monosodium-phosphate#section=pH (last visited Dec. 5, 2022). Petitioner Exhibit 1085: Disodium hydrogen phosphate, PubChem, available at https://pubchem.ncbi.nlm.nih.gov/compound/24203#section=Refractive-Index (last visited Dec. 5, 2022). Petitioner Exhibit 1086: Declaration of Dr. Paul A. Laskar Ph.D (Ex. 1014) in IPR2018-01020, executed on May 14, 2018. Petitioner Exhibit 1087: U.S. Patent No. 8,791,154 to Gamache et al., (Ex. 1001 in IPR2018-01020). Petitioner Exhibit 1088: U.S. Patent No. 6,995,186 B2 to Castillo et al., (Ex. 1005 in IPR2018-01020).
11/21/2022	11-21-2022-Petitioner	Petitioner Notice: Notice of deposition 21: Petitioner's Notice of Deposition of Paul A. Lasker, Ph.D.
10/21/2022	10-21-2022-Patent_Owner	Patent Owner PO Response to Pet 20: Patent Owner's Response Patent Owner Exhibit 2003: October 21, 2022, Declaration of Paul A. Laskar, Ph.D. Patent Owner Exhibit 2009: September 30, 2022, Deposition Transcript of Dr. Stephen R. Byrn Patent Owner Exhibit 2010: Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc., Case Nos. 18-1962-LPS, 19-1067-LPS, April 27, 2021Trial Decision, D.I. 294, D.I. 307 (D. Del. Aug. 2, 2021) Patent Owner Exhibit 2011: Reckitt Benckiser Inc. v. Tris Pharma, Inc., Case No. 09-3125-FLW, Decision on Summary Judgment, D.I. 220 (D.N.J. Dec. 2, 2011)
10/14/2022	10-14-2022-Board	Board Order: on Motion 19: ORDER Granting Petitioners Unopposed Motions for Admission Pro Hac Vice of Thomas H. Wintner 37 C.F.R. sec 42.10
9/8/2022	09-08-2022-Patent_Owner	Patent Owner Notice of Deposition 18: Updated Byrn Deposition Notice
9/1/2022	09-01-2022-Patent_Owner	Patent Owner Notice of Deposition 17: Notice of Deposition of Stephen R. Byrn, Ph.D.
8/31/2022	08-31-2022-Patent_Owner	Patent Owner Notice 15: Joint Stipulation to Modify the Scheduling Order Patent Owner Notice 16: Joint Stipulation to Modify the Scheduling Order
8/12/2022	08-12-2022-Petitioner	Petitioner Notice 14: Petitioner's Notice of Supplemental Evidence
8/2/2022	08-02-2022-Petitioner	Petitioner Motion 13: UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF THOMAS H. WINTNER Petitioner Exhibit 1059: DECLARATION OF THOMAS H. WINTNER
7/29/2022	07-29-2022-Patent_Owner	Patent Owner Objection 12: Patent Owner's Objections to Evidence
7/19/2022	07-19-2022-Petitioner	Petitioner Notice 11: Petitioner's Updated Mandatory Notices
7/15/2022	07-15-2022-Board	Event: Petition Institution (Granted) Board Institution Decision: Grant 9: DECISION Granting Institution of Inter Partes Review 35 U.S.C. 314 Board Other: other 10: Scheduling Order
5/24/2022	05-24-2022-Patent_Owner	Patent Owner Reply 8: Patent Owner's Sur-Reply
5/23/2022	05-23-2022-Board	Board Exhibit 3001: Exhibit 3001
5/17/2022	05-17-2022-Petitioner	Petitioner Reply 7: Petitioner's Reply to Patent Owner's Preliminary Response Petitioner Exhibit 1056: FDA Approval Package for Akorn Inc., Atropine Sulfate Ophthalmic Solution, USP, 1%, available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206289Orig1s000Approv.pdf (last visited 5/12/2022) Petitioner Exhibit 1057: DailyMed database webpages for ATROPINE (atropine sulfate) solution/ drops, Akorn Inc., available at https://dailymed.nlm.nih.gov/dailymed/ (sites last visited 5/12/2022) Petitioner Exhibit 1058: August 4, 2017 FDA Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review for NDA 206289 (Akorn Inc., Atropine Sulfate Ophthalmic Solution, USP 1%)
4/18/2022	04-18-2022-Patent_Owner	Event: Preliminary Response Patent Owner Preliminary Response 6: Patent Owner's Preliminary Response Patent Owner Exhibit 2001: EX2001 - Laskar Declaration Patent Owner Exhibit 2002: EX2002 - Laskar CV Patent Owner Exhibit 2004: EX2004 - PAIR - PAIRPrintServlet Patent Owner Exhibit 2005: EX2005 - Internet Archives Affidavit Patent Owner Exhibit 2006: EX2006 - Amneal Pharms FDA Page Patent Owner Exhibit 2007: EX2007 - Apotex FDA Page 215624 Patent Owner Exhibit 2008: EX2008 - Intl Medication Sys FDA Page
1/18/2022	01-18-2022-Board	Board Notice: Notice filing date accorded 3: Notice: Notice filing date accorded
1/18/2022	01-18-2022-Patent_Owner	Patent Owner Mandatory Notice 4: Patent Owner's Mandatory Notices Patent Owner Power of Attorney 5: Patent Owner's Power of Attorney
1/7/2022	01-07-2022-Petitioner	Event: Petition Petitioner Petition 1: Petition for Inter Partes Review of U.S. Patent No. 10,940,145 Petitioner Power of Attorney 2: Petitioner's Power of Attorney Petitioner Exhibit 1001: U.S. Patent No. 10,940,145 to Ostrow et al. Petitioner Exhibit 1002: Declaration of Dr. Stephen Byrn, Ph.D. Petitioner Exhibit 1003: Chia et al., Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2), OPHTHALMOLOGY 119(2): 347��354 (2012) Petitioner Exhibit 1004: Akorn Atropine CareTM (atropine sulfate ophthalmic solution), NDA 206289 Product Label (Revised July 2014) Petitioner Exhibit 1005: Albert A. Kondritzer & Peter Zvirblis, Stability of Atropine in Aqueous Solution, J. AM. PHARM. ASSOC. 46(9):531��535 (1957) Petitioner Exhibit 1006: International Publication No. WO 2014/182620 to Wu et al. Petitioner Exhibit 1007: Lund et al., The Kinetics of Atropine and Apoatropine in Aqueous Solutions, ACTA CHEM. SCAND. 22:3085-3097 (1968) Petitioner Exhibit 1008: McBrien et al., Point-Counterpoint. How does atropine exert its anti-myopia effects?, OPHTHALMIC & PHYSIOL. OPT. 33:373��378 (2013) Petitioner Exhibit 1009: U.S. Patent Publication No. 2007/0254914 to Wu et al. Petitioner Exhibit 1010: Chua et al., Atropine for the Treatment of Childhood Myopia, OPHTHALMOLOGY 113(12):2285��2291 (2006) Petitioner Exhibit 1011: Shih et al., An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression, ACTA OPHTHALMOL. SCAND. 79:233��236 (2001) Petitioner Exhibit 1012: Lee et al., Prevention of Myopia Progression with 0.05% Atropine Solution, J. OCUL. PHARMACOL. & THER. 22(1):41��46 (2006) Petitioner Exhibit 1013: Fang et al., Prevention of Myopia Onset with 0.025% Atropine in Premyopic Children, J. OCUL. PHARMACOL. & THER. 26(4):341��345 (2010) Petitioner Exhibit 1014: Shih et al., Effects of Different Concentrations of Atropine on Controlling Myopia in Myopic Children, J. OCUL. PHARMACOL. & THER. 15(1):85��90 (1999) Petitioner Exhibit 1015: Wu et al., The Long-Term Results of Using Low-Concentration Atropine Eye Drops for Controlling Myopia Progression in Schoolchildren, J. OCUL. PHARMACOL. & THER. 27(5):461��466 (2011) Petitioner Exhibit 1016: Chia et al., Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%, AM. J. OPHTHALMOL. 157(2):451��457.e1 (2014) Petitioner Exhibit 1017: Zvirblis et al., The Kinetics of the Hydrolysis of Atropine, J. AM. PHARM. ASSOC. 45(7): 450��454 (1956) Petitioner Exhibit 1018: USP 24 Official Monographs / Atropine, THE UNITED STATES PHARMACOPEIA 177-180 (2000) Petitioner Exhibit 1019: John D. Mullins & Gerald Hecht, Pharmaceutical Necessities and Ophthalmic Preparations, in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, VOLUME II 1380��1416, 1563��1576 (Alfonso R. Gennaro ed., 19th ed. 1995) Petitioner Exhibit 1020: Drugs@FDA: FDA-Approved Drugs: AKORN NDA 206289, U.S. FDA, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206289 Petitioner Exhibit 1021: Application Number: 206289Orig1s000 Summary Review, U.S. FDA CTR. FOR DRUG EVALUATION & RES. (July 18, 2014) Petitioner Exhibit 1022: Akorn Atropine CareTM (atropine sulfate ophthalmic solution), Advertisement Rev. 08/11 Petitioner Exhibit 1023: Akorn Atropine CareTM (Atropine Sulfate Ophthalmic Solution, 1%), Product Label Rev. 06/08 Petitioner Exhibit 1024: Schier et al., Preparing for Chemical Terrorism: Stability of Injectable Atropine Sulfate, ACAD. EMERG. MED. 11(4):329��334 (2004) Petitioner Exhibit 1025: European Patent Publication No. 0332826 to Tashma Petitioner Exhibit 1026: Anschel et al., Parenteral Formulation VI: Hydrolytic Degradation of Esters in Parenteral Solutions, BULLETIN PARENTER. DRUG ASSOC. 26(6):271��289 (1972) Petitioner Exhibit 1027: Sumie Yoshioka & Valentino J. Stella, STABILITY OF DRUGS AND DOSAGE FORMS 228 (2007) Petitioner Exhibit 1028: Ann E. Mair & G. Smith, The Detection of Atropine and Its Degradation Products by Thin-Layer Chromatography, J. CLIN. PHARM. 2:101-104 (1977) Petitioner Exhibit 1029: Parmar et al., The solution, solid state stability and kinetic investigation in degradation studies of lercanidipine: study of excipients compatibility of lercanidipine, PHARM. DEV. TECHNOL. 17(6):730-740 (2011) Petitioner Exhibit 1030: Deliang Zhou et al., Chapter 5 �� Drug Stability and Degradation Studies, in DEVELOPING SOLID ORAL DOSAGE FORMS PHARMACEUTICAL THEORY AND PRACTICE 87-124 (Yihong Qiu et al. eds., 2009) Petitioner Exhibit 1031: R.B. Taylor & A.S. Shivji, A critical appraisal of drug stability testing methods, PHARM. RES. 4(3):177-80 (1987) Petitioner Exhibit 1032: U.S. Patent No. 5,716,952 to WoldeMussie et al. Petitioner Exhibit 1033: U.S. Patent Publication No. 2012/0015035 to Wildsoet et al. Petitioner Exhibit 1034: Garcia-Valldecabres et al., pH Stability of ophthalmic solutions, OPTOMETRY 75(3):161��168 (2004) Petitioner Exhibit 1035: Lallemand et al., Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb, J. DRUG DELIV. 2012:1��16 (2012) Petitioner Exhibit 1036: Erica L. Fletcher & Noel A. Brennan, The effect of solution tonicity on the eye, CLIN. & EXP. OPTOM. 76.1:17-21 (1993) Petitioner Exhibit 1037: U.S. Patent No. 10,842,787 File History - Part 1 Petitioner Exhibit 1037: U.S. Patent No. 10,842,787 File History - Part 2 Petitioner Exhibit 1037: U.S. Patent No. 10,842,787 File History - Part 3 Petitioner Exhibit 1037: U.S. Patent No. 10,842,787 File History - Part 4 Petitioner Exhibit 1037: U.S. Patent No. 10,842,787 File History - Part 5 Petitioner Exhibit 1038: Pfannkoch, The Preparation of Buffers and Other Solutions: A Chemist��s Perspective, MOLECULAR BIOLOGY PROBLEM SOLVER: A LABORATORY GUIDE Ch. 3:31��47 (Alan S. Gerstein ed., 2001) Petitioner Exhibit 1039: HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 5��7, 193��196, 281��284, 351��352, 741��742, 984��989 (Raymond C. Rowe et al. eds., 7th ed. 2012) - Part 1 Petitioner Exhibit 1039: HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 5��7, 193��196, 281��284, 351��352, 741��742, 984��989 (Raymond C. Rowe et al. eds., 7th ed. 2012) - Part 2 Petitioner Exhibit 1040: Waterman et al., Hydrolysis in Pharmaceutical Formulations, PHARM. DEV. & TECH. 7(2):113��146 (2002) Petitioner Exhibit 1041: Certified English Translation of Yuanda Wen, Preparation and Clinical Curative Effects of 0.05% Atropine Sulfate Eye Drops, CHINA PHARMACIST 11(2):194��196 (2008) Petitioner Exhibit 1042: M. R. W. Brown & D. A. Norton, The Preservation of Ophthalmic Preparations, J. SOC. COSMETIC CHEMISTS 16:369��393 (1965) Petitioner Exhibit 1043: Certified English Translation of CN 101049287A to Wu Peichang et al. Petitioner Exhibit 1044: Rajpal et al., Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence, PATIENT PREFER ADHERENCE 8:925��31 (2014) Petitioner Exhibit 1045: Chowhan et al., Ophthalmic Preparations, in REMINGTON: THE SCIENCE & PRACTICE OF PHARMACY 907-929 (22d ed. 2013) Petitioner Exhibit 1046: Kirchhoff et al., Analysis of atropine, its degradation products and related substances of natural origin by means of reversed-phase high-performance liquid chromatography, J. CHROMATOGRAPHY A 1046:115��120 (2004) Petitioner Exhibit 1047: PB Patel et al., Ophthalmic Drug Delivery System: Challenges and Approaches, SYSTEMATIC REVIEWS IN PHARMACY 1(2):113��120 (2010) Petitioner Exhibit 1048: International Publication No. WO 2012/161655 to Donald Tan and Wei Han Chua Petitioner Exhibit 1049: U.S. Patent Publication No. 2012/0203161 to Herekar Petitioner Exhibit 1050: English Translation of Jinshen Li, Preparation and Quality Control of 0.04% Atropine Sulfate Eye Drops, CHINA PHARMACY 17(2):111��113 (2006) Petitioner Exhibit 1051: John D. Mullins & Gerald Hecht, Tonicity, Osmoticity, Osmolality and Osmolarity and Stability of Pharmaceutical Products, in REMINGTON: THE SCIENCE & PRACTICE OF PHARMACY, Volume I 613��627, 639��647 (Alfonso R. Gennaro ed., 19th ed. 1995) Petitioner Exhibit 1052: U.S. Patent No. 10,940,145 File History - Part 1 Petitioner Exhibit 1052: U.S. Patent No. 10,940,145 File History - Part 2 Petitioner Exhibit 1052: U.S. Patent No. 10,940,145 File History - Part 3 Petitioner Exhibit 1052: U.S. Patent No. 10,940,145 File History - Part 4 Petitioner Exhibit 1052: U.S. Patent No. 10,940,145 File History - Part 5 Petitioner Exhibit 1053: A. Schubert et al., Sterility of Anesthetic Multiple-Dose Vials after Opening, ANESTHESIOLOGY 62:634-636 (1985) Petitioner Exhibit 1054: MCGRAW-HILL DICTIONARY OF CHEMISTRY (2nd ed. 2003)

Supplemental Search

Search for PTAB Motions

PTAB Analytics

TTAB Analytics

Basic Search

Filters

Party Search

Advanced

Selected Courts

Recently Selected Courts

Find PTAB Decisions

PTAB Analytics

Special PTAB Alerts

Orange Book

Directly Search Federal Courts

Search Trademark ...

Search millions of cases and get court filings, fast docket alerts, and case analytics.

Request a Demo or create your account.

Lawyer? Your firm may have a group account, ask us and we'll let you know.

Patent Owner

Petitioner

Keyboard shortcuts

Filtering / Searching the Docket

Interactive Timeline

Eyenovia, Inc. v. Sydnexis, Inc.

IPR2022-00414 | Patent Trial and Appeal Board

Interested in this case?

Event:

Event:

Event:

Event:

Event:

Alert Sharing

STEP 2 of 2

Choose your membership type

Flat-Fee

Pay-As-You-Go Monthly

Add your payment information

Login or Join

Enter your corporate Email

Thousands of your peers are saving time and gaining a competitive advantage with Docket Alarm.

Join Docket Alarm to perform smarter legal research.

Download this document and millions of others instantly with a Docket Alarm membership.

Join Docket Alarm and start performing smarter legal research.

Start tracking this docket instantly with a Docket Alarm membership.

Join thousands of your peers and start performing smarter legal research.

STEP 1 of 2

Millions of Documents | 15 Seconds to Signup

Hi !

Welcome to Docket Alarm

Welcome to Docket Alarm!

Explore Litigation Insights andManage Your Cases

Reset Password

What is PACER?

Why do I need it?

What will I be charged?

Do other courts have fees?

Basic Free Access

Welcome

Thank you

Check Firm Account

Explore Litigation Insights and
Manage Your Cases